{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:41:33Z","timestamp":1783690893934,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Untreated neovascular age-related macular degeneration (nAMD) can lead to severe and permanent visual impairment. The chronic nature of the disease can have a significant impact on patients\u2019 quality of life and an economic and time burden on medical retina (MR) services, with the care need outweighing the growth of resources that clinical services can access. The introduction of a new treatment into clinical services can be challenging, especially for services that are already under capacity constraints. Guidance for practical implementation is therefore helpful. Roundtable meetings, facilitated by Novartis UK, between a working group of MR experts with experience of leading and managing NHS retinal services in the intravitreal era were conducted between 2020 and 2021. These meetings explored various aspects and challenges of introducing a new anti-vascular endothelial growth factor (VEGF) therapy to the UK medical retina services. Provision of clear expert recommendations and practical guidance nationally, that can be adapted locally as required to support clinicians and healthcare professionals (HCPs), is valuable in supporting the introduction of a new anti-VEGF therapy within the NHS environment. The experts provide ophthalmologic HCPs with a collation of insights and recommendations to support the introduction and delivery of brolucizumab in their local service in the face of current and projected growth in demand for retina care.<\/jats:p>","DOI":"10.1038\/s41433-022-02008-3","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T18:05:06Z","timestamp":1647885906000},"page":"1725-1734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice"],"prefix":"10.1038","volume":"36","author":[{"given":"Ian","family":"Pearce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5028-7984","authenticated-orcid":false,"given":"Winfried","family":"Amoaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2141-4512","authenticated-orcid":false,"given":"Clare","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4448-8162","authenticated-orcid":false,"given":"Faruque","family":"Ghanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Nosek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6126-6476","authenticated-orcid":false,"given":"James","family":"Talks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5392-5133","authenticated-orcid":false,"given":"Yit","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"2008_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bjophthalmol-2013-304033","volume":"98","author":"RR Bourne","year":"2014","unstructured":"Bourne RR, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990\u20132010. Br J Ophthalmol. 2014;98:629\u201338.","journal-title":"Br J Ophthalmol"},{"key":"2008_CR2","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","volume":"124","author":"JM Colijn","year":"2017","unstructured":"Colijn JM, Buitendijk GHS, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP, et al. Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology. 2017;124:1753\u201363.","journal-title":"Ophthalmology"},{"key":"2008_CR3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41433-020-0864-6","volume":"34","author":"F Rahman","year":"2020","unstructured":"Rahman F, Zekite A, Bunce C, Jayaram H, Flanagan D. Recent trends in vision impairment certifications in England and Wales. Eye. 2020;34:1271\u20138.","journal-title":"Eye"},{"key":"2008_CR4","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/bjophthalmol-2020-317434","volume":"105","author":"V Daien","year":"2021","unstructured":"Daien V, Finger RP, Talks JS, Mitchell P, Wong TY, Sakamoto T, et al. Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence. Br J Ophthalmol. 2021;105:1475\u201379","journal-title":"Br J Ophthalmol."},{"key":"2008_CR5","unstructured":"WHO. World Health Organisation. Priority eye diseases: age-related macular degeneration. http:\/\/www.who.int\/blindness\/causes\/priority\/en\/index8.html#. Accessed July 2021."},{"key":"2008_CR6","unstructured":"NICE. TA155. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. https:\/\/www.nice.org.uk\/guidance\/ta155. Accessed July 2021."},{"key":"2008_CR7","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"2008_CR8","first-page":"198","volume":"119","author":"NM Bressler","year":"2001","unstructured":"Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study G. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119:198\u2013207.","journal-title":"Arch Ophthalmol"},{"key":"2008_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160:725\u201331 e721.","journal-title":"Am J Ophthalmol"},{"key":"2008_CR10","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2147\/OPTH.S233061","volume":"14","author":"W Amoaku","year":"2020","unstructured":"Amoaku W, Bailey C, Downey L, Gale RP, Ghanchi F, Hamilton R, et al. Providing a safe and effective intravitreal treatment service: strategies for service delivery. Clin Ophthalmol. 2020;14:1315\u201328.","journal-title":"Clin Ophthalmol"},{"key":"2008_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-2836-0","volume":"18","author":"L Pezzullo","year":"2018","unstructured":"Pezzullo L, Streatfeild J, Simkiss P, Shickle D. The economic impact of sight loss and blindness in the UK adult population. BMC Health Serv Res. 2018;18:63.","journal-title":"BMC Health Serv Res"},{"key":"2008_CR12","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"2008_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193\u2013201.","journal-title":"Ophthalmology"},{"key":"2008_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57\u201365 e55.","journal-title":"Ophthalmology"},{"key":"2008_CR15","unstructured":"NICE. NG82. Age-related macular degeneration. 2021. nice.org.uk\/guidance\/ng82."},{"key":"2008_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2165\/11318550-000000000-00000","volume":"24","author":"SA Mousa","year":"2010","unstructured":"Mousa SA, Mousa SS. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. BioDrugs. 2010;24:183\u201394.","journal-title":"BioDrugs"},{"key":"2008_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/path.4266","volume":"232","author":"M van Lookeren Campagne","year":"2014","unstructured":"van Lookeren Campagne M, LeCouter J, Yaspan BL, Ye W. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol. 2014;232:151\u201364.","journal-title":"J Pathol"},{"key":"2008_CR18","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144\u201367.","journal-title":"Br J Ophthalmol"},{"key":"2008_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128:89\u201399.","journal-title":"Ophthalmology"},{"key":"2008_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"2008_CR21","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388\u201398.","journal-title":"Ophthalmology"},{"key":"2008_CR22","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382:1258\u201367.","journal-title":"Lancet"},{"key":"2008_CR23","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"IS Investigators","year":"2012","unstructured":"Investigators IS, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399\u2013411.","journal-title":"Ophthalmology"},{"key":"2008_CR24","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"MG Maguire","year":"2016","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials Research G, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1751\u201361.","journal-title":"Ophthalmology"},{"key":"2008_CR25","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1097\/IAE.0000000000001753","volume":"38","author":"VL Qin","year":"2018","unstructured":"Qin VL, Young J, Silva FQ, Conti FF, Singh RP. Outcomes of patients with exudative age-related macular degeneration treated with antivascular endothelial growth factor therapy for three or more years: a review of current outcomes. Retina. 2018;38:1500\u20138.","journal-title":"Retina"},{"key":"2008_CR26","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/eye.2017.143","volume":"31","author":"A Lotery","year":"2017","unstructured":"Lotery A, Griner R, Ferreira A, Milnes F, Dugel P. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. Eye. 2017;31:1697\u2013706.","journal-title":"Eye"},{"key":"2008_CR27","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","volume":"36","author":"LN Kim","year":"2016","unstructured":"Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36:1418\u201331.","journal-title":"Retina"},{"key":"2008_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","volume":"65","author":"H Mehta","year":"2018","unstructured":"Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127\u201346.","journal-title":"Prog Retin Eye Res"},{"key":"2008_CR29","first-page":"353","volume":"101","author":"T Wecker","year":"2017","unstructured":"Wecker T, Ehlken C, Buhler A, Lange C, Agostini H, Bohringer D, et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol. 2017;101:353\u20139.","journal-title":"Br J Ophthalmol"},{"key":"2008_CR30","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mones","year":"2021","unstructured":"Mones J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050\u20139.","journal-title":"Ophthalmology"},{"key":"2008_CR31","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2147\/OPTH.S269596","volume":"15","author":"M Groppe","year":"2021","unstructured":"Groppe M, Bindra MS. Restructuring wet age-related macular degeneration services during the COVID-19 pandemic to allow Social Distancing Outpatient Clinics (SDOC). Clin Ophthalmol. 2021;15:651\u20139.","journal-title":"Clin Ophthalmol"},{"key":"2008_CR32","unstructured":"Beovu. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/beovu-epar-product-information_en.pdf. Accessed July 2021."},{"key":"2008_CR33","unstructured":"NICE. TA672. Brolucizumab for treating wet age-related macular degeneration. 2021. https:\/\/www.nice.org.uk\/guidance\/ta672."},{"key":"2008_CR34","unstructured":"RCOphth. Royal College of Ophthalmologists. AMD Services Commissioning Guidance. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2021\/02\/AMD-Commissioning-Guidance-Consultation.pdf. Accessed July 2021."},{"issue":"Suppl 1","key":"2008_CR35","first-page":"31","volume":"118","author":"German Society of O, German Retina S, Professional Association of German O.","year":"2021","unstructured":"German Society of O, German Retina S, Professional Association of German O. Statement of the German Ophthalmological Society (DOG), the German Retina Society (GRS), and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration: Status February 2020. Ophthalmologe. 2021;118 Suppl 1:31\u201339.","journal-title":"Ophthalmologe"},{"key":"2008_CR36","unstructured":"Lucentis. Summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/307\/smpc#gref. Accessed July 2021."},{"key":"2008_CR37","unstructured":"Eylea. Summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/2879\/smpc#gref. Accessed July 2021."},{"key":"2008_CR38","unstructured":"Zarbin M, Guruprasad B, Yu J, Glassberg M, Fevrier H, LaPrise A, et al. Profiles and early outcomes of patients who initiated brolucizumab for neovascular (wet) age-related macular degeneration (AMD) in the IRIS registry and Komodo database. PO395 Presented at the American Academy of Ophthalmology Annual Meeting. 13-15 November, 2020."},{"key":"2008_CR39","unstructured":"Novartis. NCT04005352. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04005352. Accessed August 2021."},{"key":"2008_CR40","unstructured":"NICE. British National Formulary. Adverse reactions to drugs. https:\/\/bnf.nice.org.uk\/guidance\/adverse-reactions-to-drugs.html. Accessed July 2021."},{"key":"2008_CR41","doi-asserted-by":"publisher","first-page":"e12817","DOI":"10.1111\/dth.12817","volume":"32","author":"E Thomaidou","year":"2019","unstructured":"Thomaidou E, Ramot Y. Injection site reactions with the use of biological agents. Dermatol Ther. 2019;32:e12817.","journal-title":"Dermatol Ther"},{"key":"2008_CR42","unstructured":"Beovu. Package Information Leaflet. https:\/\/www.medicines.org.uk\/emc\/files\/pil.11145.pdf. Accessed July 2021."},{"key":"2008_CR43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye. 2015;29:721\u201331.","journal-title":"Eye"},{"issue":"Suppl 1","key":"2008_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-018-0300-3","volume":"33","author":"RP Gale","year":"2019","unstructured":"Gale RP, Mahmood S, Devonport H, Patel PJ, Ross AH, Walters G. et al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye. 2019;33 Suppl 1:1\u201321.","journal-title":"Eye"},{"key":"2008_CR45","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27:787\u201394.","journal-title":"Eye"},{"key":"2008_CR46","unstructured":"Hospital. ME Moorfields Eye Hospital. Endophthalmitis. https:\/\/www.moorfields.nhs.uk\/condition\/endophthalmitis. Accessed July 2021."},{"key":"2008_CR47","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/eye.2014.231","volume":"29","author":"PS Severn","year":"2015","unstructured":"Severn PS, Hamilton R. The incidence of serious complications associated with intravitreal therapy in a quaternary ARMD service (2008-14). Eye. 2015;29:150.","journal-title":"Eye"},{"key":"2008_CR48","unstructured":"ASRS. American Society of Retina Specialists. Safety Review Committee Report. https:\/\/www.asrs.org\/clinical\/clinical-updates\/4013\/Member-Update-Novartis-Appointed-Safety-Review-Committee-Reports-Initial-Broluci. Accessed July 2021."},{"key":"2008_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.oret.2021.05.003","volume":"6","author":"M Singer","year":"2022","unstructured":"Singer M, Albini TA, Seres A, Baumal CR, Parikh S, Gale R, et al. Clinical characteristics and outcomes of eyes with intraocular inflammation after brolucizumab: Post hoc analysis of HAWK and HARRIER. Ophthalmol Retina. 2022:6:97\u2013108","journal-title":"Ophthalmol Retina"},{"key":"2008_CR50","unstructured":"Novartis. NCT03710564. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03710564. Accessed August 2021."},{"key":"2008_CR51","unstructured":"Novartis. Novartis reports one year results of Phase III MERLIN study evaluating Beovu\u00ae every four week dosing and provides update on Beovu clinical program. 2021 https:\/\/www.novartis.com\/news\/media-releases\/novartis-reports-one-year-results-phase-iii-merlin-study-evaluating-beovu-every-four-week-dosing-and-provides-update-beovu-clinical-program. Accessed Mar 2022."},{"key":"2008_CR52","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","volume":"140","author":"AM Khanani","year":"2022","unstructured":"Khanani AM, Zarbin MA, Barakat MR, Albini TA, Kaiser PK, Guruprasad B, et al. Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS registry and komodo healthcare map. JAMA Ophthalmol. 2022;140:20\u20138","journal-title":"JAMA Ophthalmol"},{"key":"2008_CR53","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","volume":"5","author":"CR Baumal","year":"2021","unstructured":"Baumal CR, Bodaghi B, Singer M, Tanzer DJ, Seres A, Joshi MR, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2021;5:519\u201327.","journal-title":"Ophthalmol Retina"},{"key":"2008_CR54","unstructured":"Heier JS, Rosenbaum JT, Barakat MR, Khanani AM, Singer M, Dick AD, et al. Assessing characteristics of patients with or without intraocular inflammation (IOI) in the brolucizumab treatment arms from the HAWK and HARRIER, Phase 3 studies. American Academy of Ophthalmology; 2020."},{"key":"2008_CR55","unstructured":"Ip M, Albini T, Zarbin M, MacCumber M, Yu J, Prasad GB, et al. The brolucizumab experience thus far: a health economics and outcomes research analysis. American Academy of Ophthalmology; 2020."},{"key":"2008_CR56","unstructured":"Machin J, Navaratnam A, Hutton M, Hammond S, Vernon H, Briggs T. The getting it right first time (GIRFT) and NHS resolution best practice guide for clinicians and managers. Learning from litigation claims. https:\/\/www.gettingitrightfirsttime.co.uk\/wp-content\/uploads\/2021\/05\/Best-practice-in-claims-learning-FINAL.pdf. Accessed July 2021."},{"key":"2008_CR57","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1302\/0301-620X.98B11.37965","volume":"98-B","author":"JM Powell","year":"2016","unstructured":"Powell JM, Rai A, Foy M, Casey A, Dabke H, Gibson A, et al. The \u2018three-legged stool\u2019: a system for spinal informed consent. Bone Jt J. 2016;98-B:1427\u201330.","journal-title":"Bone Jt J"},{"key":"2008_CR58","unstructured":"NHS. Consent to treatment. https:\/\/www.nhs.uk\/conditions\/consent-to-treatment\/. Accessed July 2021."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02008-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02008-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02008-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T07:05:56Z","timestamp":1660892756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02008-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2008"],"URL":"https:\/\/doi.org\/10.1038\/s41433-022-02008-3","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"26 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WA has received research grants from Allergan, Bayer, CentreVue, Boerhinger Ingelheim, Novartis; Educational travel grants from Alimera, Allergan, Bayer, Novartis and honoraria for Advisory Board Memberships from Abbvie, Alimera, Allergan, Bayer, Novartis, and Roche. CB has received grant funding for advisory board work \/travel support from Novartis, Bayer, Roche, Bristol Eye Hospital and has received research funding from Bayer, Novartis, Allergan, Boehringer\u2013Ingelheim, and Roche. LD has received research funding from Allergan, Bayer, Novartis, Alimera, Roche, educational travel grants from Allergan, Bayer, Novartis and Honoraria for Advisory Boards\/speakers fees from Alimera, Bayer, Novartis, Roche, Bausch and Lomb. RG has conducted consultancy-advisory boards for Novartis, Bayer and Allergan, Alimera, Santen, received educational travel grants from Novartis, Bayer, Allergan, Heidelberg and departmental research from Allergan, Bayer, Novartis, and Roche. FG has received honorarium for consultancy-advisory boards from Alimera, Allergan, Bayer, Novartis, Oxford BioElectronics, Roche; educational travel grants from Allergan, Bayer, Novartis and departmental research grants from Allergan, Bayer, Boehringer Ingelheim, Chengdu Pharma, Novartis, PanOptica, Roche. RH has received non-financial assistance, personal fees, and been advisor to Novartis, Bayer, Allergan, Roche, and Ellex. SM has received lecture fees from Bayer and Novartis, consultancy fees from Alimera, Bayer, Novartis, Travel fees from Bayer and Novartis and Research funding from Bayer, Novartis and Roche. GM has conducted consultancy-advisory boards for Novartis, Bayer and Allergan, received educational travel grants from Novartis, Bayer, Allergan; and departmental research from Allergan, Bayer, Boehringer Ingelheim, Chengdu Pharma, Novartis, PanOptica, and Roche. JN has received honorarium from Novartis, Bayer and Zeiss. YY has received personal fees and non-financial assistance from Novartis, Bayer, Allergan, and Roche. IP has received lecture fees from Allergan, Bayer, Heidelberg and Novartis, consultancy fees from Allergan, Alimera, Bayer and Novartis and travel fees from Allergan, Bayer and Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}